Superbug and viral pathogen treatment developer Recce Pharmacetical (ASX:RCE)’s unapproved drug R327 has successfully saved a patient suffering a life-threatening illness.
Despite not undertaking clinical trials, nasal treatment R327 was accessible to the individual via Category A of the Therapeutic Goods Administration special access scheme. Recce (ASX:RCE) intends to proceed with clinical trials for the product.
The news has shot Recce’s shares up 5.1 per cent to $1.03
Copyright 2021 – Finance News Network
05 Nov 2019 - Communications and IT Services Provider Speedcast (ASX:SDA), has announced that S&P Global has lowered its issuer credit rating to B- from B, and maintained the outlook as Negative.
31 Mar 2020 - Wesfarmers (ASX:WES) today announced that trades have been executed for the sale of 5.2 per cent of the issued capital in Coles Group (ASX:COL) for $1.06 billion.
25 May 2022 - Three iron ore companies that have hit 52-week highs. A deep dive on the backdrop and why this could be the case, featuring TerraCom (ASX:TER), Stanmore Resources (ASX:SMR), and Grange Resources (ASX:GRR).
09 Jan 2020 - Lithium explorer and developer Lake Resources (ASX:LKE) has confirmed that battery grade lithium carbonate with 99.9 per cent purity has been produced with very low impurities from Lake’s Kachi Lithium Brine Project.
19 May 2020 - Centuria Property Funds, the responsible entity for Centuria Office REIT (ASX:COF), has secured a seven year debt facility from the world’s largest cooperative financial institution Credit Agricole.
22 Jun 2020 - Property company Stockland (ASX:SGP) says preliminary draft revaluations indicate a reduction in the book value of its portfolio of approximately 6 per cent.
08 Sep 2020 - Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp-derived cannabinoid-based oral care products subsidiary.
